Literature DB >> 25302477

MiR-122 decreases HCV entry into hepatocytes through binding to the 3' UTR of OCLN mRNA.

Hossein Sendi1, Marjan Mehrab-Mohseni, David M Foureau, Sriparna Ghosh, Tracy L Walling, Nury Steuerwald, Philippe J Zamor, Keith J Kaplan, Carl Jacobs, William A Ahrens, Mark W Russo, Mark G Clemens, Laura W Schrum, Herbert L Bonkovsky.   

Abstract

BACKGROUND & AIMS: Analysis in silico suggests that occludin (OCLN), a key receptor for HCV, is a candidate target of miR-122; the most abundant hepatic micro RNA. We aimed to determine if miR-122 can decrease HCV entry through binding to the 3' UTR of OCLN mRNA.
DESIGN: Huh7.5 cells were cotransfected with luciferase construct containing 3' UTR of OCLN (pLuc-OCLN) and with selected miRNAs (0-50 nM) and luciferase activity was measured. Huh7.5 cells were also infected by viral particles containing lenti-miR122 genome or control virus. After 48 h, the cells were infected with HCV pseudo-particles (HCVpp) and VSV pseudo-particles (VSVpp). After 72 h of infection, luciferase activity was measured and HCVpp activity was normalized to VSVpp activity.
RESULTS: miR-122 binds to the 3'-UTR of OCLN and down-regulates its expression; cotransfection of miR-122 mimic with pLuc-OCLN resulted in a significant decrease in luciferase activity [by 55% (P < 0.01)], while a non-specific miRNA and a mutant miR-122 did not have any effect. miR-122 mimic significantly down-regulated [by 80% (P < 0.01)] OCLN protein in Huh7.5 cells. Accordingly, patients with chronic hepatitis C and higher levels of hepatic miR-122 have lower hepatic expression of OCLN. Immuno-fluorescence imaging showed a decrease in colocalization of OCLN and CLDN following miR-122 over-expression in HCV infected cells. Huh7.5 cells transiently expressing Lenti-miR122 system showed 42% (P < 0.01) decrease in HCV entry.
CONCLUSION: This study uncovers a novel antiviral effect of miR-122 on human liver cells and shows that over-expression of miR-122 can decrease HCV entry into hepatocytes through down-regulation of OCLN.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis; hepatitis C; liver; micro RNA; occludin

Mesh:

Substances:

Year:  2014        PMID: 25302477     DOI: 10.1111/liv.12698

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Exosomes containing miR-122-5p secreted by LPS-induced neutrophils regulate the apoptosis and permeability of brain microvascular endothelial cells by targeting OCLN.

Authors:  Qingfeng Li; Anna Nong; Zhijing Huang; Yun'an Xu; Kebin He; Yuying Jia; Yueyan Huang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

2.  Entry Inhibitors of Hepatitis C Virus.

Authors:  Xi-Jing Qian; Zhong-Tian Qi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  MicroRNAs: Role in Hepatitis C Virus pathogenesis.

Authors:  Shubham Shrivastava; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  Genes Dis       Date:  2015-03-01

Review 4.  MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Authors:  Amir Abbas Momtazi; Maciej Banach; Matteo Pirro; Evan A Stein; Amirhossein Sahebkar
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 5.  miRNAs regulate immune response and signaling during hepatitis C virus infection.

Authors:  Huange Zhu; Yan Geng; Qian He; Miaoxian Li
Journal:  Eur J Med Res       Date:  2018-04-18       Impact factor: 2.175

Review 6.  Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2022-08-15       Impact factor: 5.818

Review 7.  The involvement of microRNAs in HCV and HIV infection.

Authors:  Nicky Joshi; Madhuri Chandane Tak; Anupam Mukherjee
Journal:  Ther Adv Vaccines Immunother       Date:  2022-07-05

8.  Dysregulated Serum MicroRNA Expression Profile and Potential Biomarkers in Hepatitis C Virus-infected Patients.

Authors:  Shaobo Zhang; Xiaoxi Ouyang; Xin Jiang; Dayong Gu; Yulong Lin; S K Kong; Weidong Xie
Journal:  Int J Med Sci       Date:  2015-07-16       Impact factor: 3.738

Review 9.  Entry inhibitors: New advances in HCV treatment.

Authors:  Xi-Jing Qian; Yong-Zhe Zhu; Ping Zhao; Zhong-Tian Qi
Journal:  Emerg Microbes Infect       Date:  2016-01-06       Impact factor: 7.163

Review 10.  siRNA Versus miRNA as Therapeutics for Gene Silencing.

Authors:  Jenny K W Lam; Michael Y T Chow; Yu Zhang; Susan W S Leung
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-15       Impact factor: 10.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.